July 23, 2020 -- Ampio Pharmaceuticals has begun patient enrollment for its previously announced COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.
Ampion is based on an immunomodulatory molecule derived from the N-terminus of the human serum albumin. The trial will evaluate its intravenous application as a treatment for patients with COVID-19 who are on supplemental oxygen.